recombinant FVIIa (rFVIIa)

08/01/2009 - "Although rFVIIa administration seemed helpful in controlling life-threatening hemorrhage, patients requiring higher doses (30 to 70 microg/kg) had a dramatically higher incidence of serious thromboembolic events."
04/01/2006 - "After administration of the second dose of rFVIIa (120 microg/kg per dose, every 2 h), the active bleeding subsided dramatically and a significant improvement in the oxygenation index was seen 8 h after the third dose of rFVIIa treatment. "
03/01/1998 - "Of 103 evaluable surgical bleeding episodes, the response to treatment with rFVIIa was considered to be either excellent or effective in 81%, 86% and 92% of major, minor and dental bleeding episodes, respectively. "
12/01/2008 - "This study demonstrated that three doses of rFVIIa given in blunt traumatic hemorrhage yielded a significant reduction of 2.6 of red blood cells used. "
04/01/2013 - "Patients with major bleeding treated with rFVIIa showed improved hemostasis with rapid normalization of coagulation variables. "

01/11/2011 - "Clinically significant benefits of recombinant factor VIIa as a general hemostatic agent in patients without hemophilia remain unproven. "
03/01/2008 - "rFVIIa has been shown effective for prophylaxis during elective surgery and has therefore improved the feasibility of orthopedic surgery in hemophilia patients with high-titer inhibitors. "
10/01/2003 - "In conclusion, should a TF-independent mechanism be involved in the efficacy of rFVIIa in patients with hemophilia, the superactive rFVIIa variants studied here might be clinically advantageous, as both procoagulant and antifibrinolytic potencies are significantly enhanced compared with those of wild-type rFVIIa. "
01/01/2012 - "Regarding patients with inhibitors, the advent of APCCs and rFVIIa has made major orthopaedic surgery possible, leading to an improved quality of life for haemophilia patients. "
01/01/2007 - "In haemophilia patients with inhibitors, recombinant factor VIIa is clinically effective in controlling mild to moderate bleeds, and in maintaining haemostasis in patients undergoing orthopaedic surgery. "

01/01/2005 - "Most published studies in trauma patients are retrospective case studies and reports, although an international, double-blind, randomized, controlled, phase II study has been conducted that reported on the efficacy of rFVIIa in reducing the amount of blood products transfused in blunt trauma patients. "
12/01/2009 - "In patients with blunt trauma alive at 48 hours, treatment with rFVIIa effected a significant reduction in the primary endpoint of 48-hour red blood cell (RBC) transfusion requirement (p = 0.02), and the safety of the dosing regimen was established. "
05/01/2007 - "(1) To define blood product requirements in patients with trauma whose underlying injuries are consistent with major blood loss; (2) to use these data to estimate the annual number of patients in Scotland who sustain significant trauma and require substantial blood product replacement; and (3) to place these data in the context of recent findings concerning the efficacy of recombinant factor VIIa in patients with major trauma. "
07/01/2005 - "Recombinant FVIIa resulted in a significant reduction in RBC transfusion in severe blunt trauma. "
10/01/2006 - "Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases."

02/15/2003 - "These data demonstrate the haemostatic efficacy of rFVIIa in a rabbit model of severe thrombocytopenia. "
01/01/2004 - "This study was undertaken to explore the effects of rFVIIa and platelet microvesicles on hemostasis in an experimental model of thrombocytopenia. "
01/01/2004 - "Platelet membrane fragments enhance the procoagulant effect of recombinant factor VIIa in studies with circulating human blood under conditions of experimental thrombocytopenia."
10/01/2002 - "Although initial observations indicate that rFVIIa may be fast, efficacious, and safe in reversing oral anticoagulant-induced bleeds and those associated with thrombocytopenia, randomised, double-blind, placebo-controlled trials must be conducted to confirm its utility in these and other investigational uses."
01/01/2002 - "A reduction in bleeding time was reported in approximately 50% of patients with thrombocytopenia and a prolonged bleeding time who participated in a trial of rFVIIa. "

11/01/2011 - "English-language data evaluating the efficacy of rFVIIa to reverse coagulopathies prior to invasive procedures in patients with liver disease were included. "
07/01/2002 - "Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy."
07/01/2002 - "The results of this study suggest that treatment with rFVIIa may offer benefit for patients with liver disease undergoing laparoscopic biopsy."
10/01/2013 - "Recombinant factor VIIa as haemostatic therapy in advanced liver disease."
05/01/2009 - "Use of recombinant factor VIIa to correct the coagulation status of individuals with advanced liver disease prior to a percutaneous liver biopsy."